

PRESS RELEASE

ProBioGen and Nouscom Sign License Agreement for ProBioGen's Technology Platform

Proprietary Duck Cell Line Serves as Large-Scale Production-Suitable Cell Substrate

Berlin, Germany, and Basel, Switzerland, June 26th, 2018: ProBioGen AG, a premier German service & technology provider for complex therapeutic glycoproteins, virus production and viral vector technologies and Nouscom AG, an oncology company dedicated to development of immunotherapies, today jointly announced signing a license agreement. Under the terms of the agreement, Nouscom will gain access to ProBioGen's proprietary production platform based on the AGE1.CR[®] duck retina cell line for production of its viral vectored vaccines.

ProBioGen's CSO, Dr Volker Sandig said: "We have developed the AGE1.CR[®] designer cell line, the chemically defined media and the process over many years, aiming to overcome challenges in the production of highly attenuated poxvirus vectors. We are very pleased to see a strong industry demand for our platform and are convinced that Nouscom's highly innovative vaccine approach will greatly benefit from it."

Nouscom's CTO, Dr Stefano Colloca added: "We are very pleased with this new partnership with ProBioGen which allows us to utilize a scalable GMP manufacturing process for production of our viral vectored vaccines. This is an important milestone in our journey towards becoming a clinical stage company."

About ProBioGen AG

ProBioGen is a premier, Berlin-based specialist for developing and manufacturing complex therapeutic glycoproteins viral vectors and vaccine technologies. Combining both state-of-the-art protein and virus platforms, based on ProBioGen's CHO.RiGHT[®] and AGE1.CR[®] expression and manufacturing platforms, respectively, together with intelligent product-specific technologies, yield biologics with optimized properties.

Rapid and integrated cell line and process development, comprehensive analytical development and following reliable GMP manufacturing is performed by a highly skilled and experienced team.

All services and technologies are embedded in a total quality management system to assure compliance with international ISO and GMP standards (EMA/FDA).

ProBioGen was founded 1994, is privately owned and located in Berlin, Germany.

For additional information, please visit ProBioGen's website, www.probiogen.de.

About Nouscom AG

Nouscom is a private oncology company developing next generation immunotherapies. Nouscom's proprietary technology platform, Exovax, harnesses the full power of the immune response by combining viral vectored genetic vaccines based on neoantigens with other immunomodulators.

Nouscom is led by an experienced management team that has worked together for many years in previous successful enterprises, including IRBM/Merck and Okairos (acquired by GSK), and are veterans in the field of genetic vaccines.

Nouscom, which was founded in 2015 and is headquartered in Basel, Switzerland with operations in Rome, Italy, is backed by international life sciences investors: 5AM, Abingworth, LSP (Life Sciences Partners) and Versant Ventures.

For more information on Nouscom, please visit the company's website at www.nouscom.com.

Contact ProBioGen AG:

Dr Gabriele Schneider

Chief Business Officer

ProBioGen AG

Goethestr. 54

13086 Berlin, Germany

Phone: +49 (0)30 924 006-0

Email: cmo@probiogen.de

Website: www.probiogen.de

Contact NousCom:

Marina Udier, PhD

Chief Operating Officer

Phone: +41 61 201 1835

Email: info@nouscom.com

Website: www.nouscom.com